IDH1 and central nervous system cancer: In particular, Cdkn2a+/+ mice with IDH1-mutant glioma had significantly longer median survival; however, they completely lost the survival advantage—and indeed faced a greater reduction in median survival—upon genetic deletion (Figure 1).